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Background: Melanoma antigen-A11 (MAGE-A11) is a primate-specific steroid receptor coregulator and proto-oncogene
expressed at increased levels in castration-resistant prostate cancer.
Results: Human p14-ARF tumor suppressor promotes the proteasomal degradation of MAGE-A11 independent of
ubiquitination.
Conclusion: MAGE-A11 is post-translationally down-regulated by the p14-ARF tumor suppressor.
Significance: Increased levels of MAGE-A11 associated with low p14-ARF promote the development of castration-resistant
prostate cancer.
X-linked primate-specific melanoma antigen-A11 (MAGE-
A11) is a human androgen receptor (AR) coactivator and proto-
oncogene expressed at low levels in normal human reproductive
tract tissues and at higher levels in castration-resistant prostate
cancer where it is required for androgen-dependent cell growth.
In this report, we show that MAGE-A11 is targeted for degrada-
tion by human p14-ARF, a tumor suppressor expressed from an
alternative reading frame of the p16 cyclin-dependent kinase
inhibitor INK4a/ARF gene. MAGE-A11 degradation by the pro-
teasome was mediated by an interaction with p14-ARF and was
independent of lysine ubiquitination. A dose-dependent inverse
relationship between MAGE-A11 and p14-ARF correlated with
p14-ARF inhibition of the MAGE-A11-induced increase in
androgen-dependent AR transcriptional activity and constitutive
activity of a splice variant-like AR. Reciprocal stabilization between
MAGE-A11 and AR did not protect against degradation promoted
by p14-ARF. p14-ARF prevented MAGE-A11 interaction with the
E2F1 oncoprotein and inhibited the MAGE-A11-induced increase
in E2F1 transcriptional activity. Post-translational down-regula-
tion of MAGE-A11 promoted by p14-ARF was independent of
HDM2, the human homologue of mouse double minute 2, an E3
ubiquitin ligase inhibited by p14-ARF. However, MAGE-A11 had a
stabilizing effect on HDM2 in the absence or presence of p14-ARF
and cooperated with HDM2 to increase E2F1 transcriptional activ-
ity in the absence of p14-ARF. We conclude that degradation of
MAGE-A11 promoted by the human p14-ARF tumor suppressor
contributes to low levels of MAGE-A11 in nontransformed cells
and that higher levels of MAGE-A11 associated with low p14-ARF
increase AR and E2F1 transcriptional activity and promote the
development of castration-resistant prostate cancer.
Prostate cancer growth and progression depend on androgen
receptor (AR)2 transcriptional signaling, which is increased by
melanoma antigen-A11 (MAGE-A11), an AR coregulator.
MAGE-A11 is a cancer-testis antigen that resides predomi-
nantly in the nucleus at low levels in normal human reproduc-
tive tract tissues and at higher levels in castration-resistant
prostate cancer (1– 6). Although named initially for its identi-
fication in melanoma (7, 8), MAGE-A11 is a coregulator of
human AR and progesterone receptor-B (1, 6, 9). MAGE-A11
increases AR transcriptional activity by binding an extended
AR NH2-terminal FXXLF motif region independent of AR
binding the active androgens, testosterone or dihydrotestos-
terone (DHT) (1). MAGE-A11 stabilizes the unliganded AR
and facilitates recruitment of p300 and p160 transcriptional
coactivators during androgen-dependent AR transactivation
(1, 10, 11).
The MAGE-A11 gene at the Xq28 locus of the MAGE gene
family on the human X chromosome evolved within the pri-
mate lineage by gene duplication and retrotransposition (12,
13). The functional dependence on MAGE-A11 for increased
human AR transcriptional activity is supported by the coevolu-
tion of X-linked human MAGE-A11 and X-linked human AR
NH2-terminal sequence flanking the FXXLF motif that medi-
ates AR interaction with MAGE-A11 and the androgen-depen-
dent AR NH2- and COOH-terminal interaction (14, 15). Rat
and mouse AR Ala33 evolved to Val33 in human AR NH2-ter-
minal sequence 23FQNLFQSVREV33, a sequence change
required for human AR to interact with MAGE-A11 (15). How-
ever, neither mouse nor rat AR Ala33 or human AR Val33 is
required for the FXXLF motif-mediated androgen-dependent
AR NH2- and COOH-terminal interaction. These findings sug-
gest that the increase in human AR transcriptional activity
resulting from the coactivator activity of MAGE-A11 evolved
more recently among primates than evolution of the androgen-
dependent AR NH2- and COOH-terminal interaction.
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In addition to AR coregulator activity, MAGE-A11 has func-
tions that directly impact the cell cycle and require complex
regulatory control. MAGE-A11 interacts with and increases the
transcriptional activity of E2F1, one of the most important tran-
scription factors and oncoproteins that promotes unscheduled
entry into S phase of the cell cycle (5). The increase in E2F1
activity by MAGE-A11 is similar to the effects of E1A, an ade-
novirus early protein that transforms cells (16). The ability of
MAGE-A11 to increase AR and E2F1 transcriptional activity
suggests that MAGE-A11 links AR to cell cycle progression and
supports the concept that cancer cells continue to grow
through the increased expression and activity of oncoproteins
such as E2F1 and MAGE-A11.
The unrestrained growth of cancer cells also depends on
deregulation of tumor suppressors, such as human p14-ARF
(ARF, alternative reading frame) and p53, proteins that protect
normal cells from tumorigenesis by arresting the cell cycle or
inducing apoptosis. ARF derives from the INK4a/ARF locus in
an alternative reading frame by alternate promoter usage and
splicing that differs from the p16 cyclin-dependent kinase
inhibitor that is more often mutated in cancer (17–21). Human
p14-ARF shares only 50% homology with the p19-ARF mouse
homologue (22), which indicates that the INK4a/ARF gene
continued to evolve late within the mammalian lineage similar
to the MAGE-A11 gene and AR NH2-terminal FXXLF motif
flanking sequence required to interact with MAGE-A11. A pri-
mary function of ARF is to bind and inhibit HDM2 (human
homologue of mouse double minute 2), an E3 ligase that ubiq-
uitinates and promotes the degradation of p53 (23–27). Inhibi-
tion of HDM2 E3 ubiquitin ligase activity by ARF increases p53
levels, which induces cell cycle arrest or apoptosis. The inhibi-
tory activity of ARF that promotes p53 accumulation requires a
unique ARF exon 1B region (22). Loss of ARF or p53 activity in
cancer cells allows cellular proto-oncogenes such as E2F1 and
MAGE-A11 to promote uncontrolled cancer cell growth and
the development of castration-resistant prostate cancer.
In this report we provide evidence that human ARF pro-
motes the proteasomal degradation of MAGE-A11 indepen-
dent of HDM2 E3 ubiquitin ligase or lysine ubiquitination. ARF
inhibited the ability of MAGE-A11 to stabilize and stimulate
AR or E2F1 transcriptional activity but did not overcome a sta-
bilizing effect of MAGE-A11 on HDM2. The findings suggest
that ARF maintains normal low levels of MAGE-A11 to limit
cell proliferation and preserve the nontransformed phenotype,
whereas low levels of ARF in prostate cancer cells contribute to
higher levels of MAGE-A11 that promote the development of
castration-resistant prostate cancer.
Experimental Procedures
DNA Vectors—Mammalian expression vectors include full-
length 1– 429-amino acid human MAGE-A11 expressed in
pSG5-MAGE, FLAG-MAGE (1), and VP-MAGE (1, 9, 11); full-
length 1–919-amino acid human AR in pCMV-AR (28),
pCMV-AR-(1– 660) NH2-terminal and DNA-binding domain
fragment (29), and pCMV-AR-(1– 660)-L26A,F27A FXXLF
motif mutant (14); and pSG5-HA-p300 (10). pCMV-E2F1 and
pBabe-puro were provided by Y. Xiong (University of North
Carolina at Chapel Hill) (5, 30). FLAG-E2F1 was provided by
E. S. Robertson (University of Pennsylvania) (31). pCI-neo-HA-
ARF and pBabe-puro-hARF coding for human ARF, pCMV-
HA2-HDM2, and pCMV-HDM2 were provided by W. G.
Yarbrough (Yale University). Luciferase reporter vectors in-
cluded PSA-Enh-Luc from M. Carey (University of California
Los Angeles) (10, 32), E2F1-Luc from J. R. Nevins (Duke Uni-
versity) (10, 33) and 5XGAL4Luc3 from D. P. McDonnell (Duke
University) (34, 35). GAL-ARF was prepared by PCR-amplify-
ing pCI-neo-HA-ARF using oligonucleotide primers to omit
the HA tag and produce a fragment cloned into EcoR1 and
BamHI sites of GAL-O. FLAG-ARF was prepared by digesting
GAL-ARF with EcoRI and BamHI and inserting the fragment
into pCMV-FLAG-b.
Expression and RNA Analysis—Cell media contained penicil-
lin, streptomycin, and 2 mM L-glutamine (Gibco, Life Technol-
ogies) as follows: human LAPC-4 cells, RPMI 1640 with 10%
FBS and 1 nM R1881 synthetic androgen agonist; 22Rv1 cells,
RPMI 1640 with 10% FBS; LNCaP cells, RPMI 1640 with 2%
FBS; human HeLa cervical cancer cells, minimal essential
medium with 10% FBS; CV1 and COS1 monkey kidney cells,
DMEM with 10% bovine calf serum and 20 mM Hepes, pH
7.2; PC-3 and DU145 cells, DMEM with 10% FBS; CWR-R1,
DMEM with additives (2).
Transcription assays were performed in 12-well plates con-
taining 1 ml medium/well plated with 5  104 HeLa cells/well
or 4  104 CV1 cells/well and transfected using 0.6 l of
X-tremeGENE DNA transfection reagent (Roche) and 50 l
medium/well. AR transcriptional activity was measured in CV1
cells using 0.25 g of PSA-Enh-Luc, 25 ng of pCMV-AR, 10 ng
of pCMV-AR-(1– 660), and/or 25 ng of pCI-neo-HA-ARF.
Endogenous E2F1 transcriptional activity was measured in
HeLa cells using 0.1 g of E2F1-Luc, 0.1 g of pSG5-MAGE,
and increasing amounts of pCI-neo-HA-ARF. Mammalian
two-hybrid assays were performed in HeLa cells using 0.1 g
of 5XGAL4Luc3, 50 ng of GAL-ARF, 50 ng of VP16 empty
vector, or wild-type or mutant VP-MAGE. The day after trans-
fection, cells were incubated for 24 h in serum-free medium
with or without 10 nM DHT. Luciferase activity measurements
represent the mean and S.E. of at least three independent
experiments.
Immunoblot analysis was performed on endogenous protein
in cancer cells or expressed protein in CV1 or COS1 cells. CV1
cells (2.3  105 cells/6-cm dish) were transfected in duplicate
6-cm dishes with 3 ml of medium using 4 l of X-tremeGENE
reagent, up to 2 g of DNA/dish and 80 l of medium/6-cm
dish, or 5  105 CV1 cells/10-cm dish with 6 ml of medium
using 8 l of X-tremeGENE reagent, 160 l of medium, and up
to 4 g DNA/dish. COS1 cells (6.2  105 cells/6-cm dish or 2 
106 cells/10-cm dish) were transfected using DEAE dextran
(36, 37).
Control and human p14-ARF retrovirus derived from pBabe-
puro or pBabe-puro-hARF retroviral vectors were prepared
using HEK293T cells. Retrovirus in 0.25 ml of HEK293T cell
media was added to 2  106 LAPC-4 cells/well or 6.2  105
HeLa cells/well in 6-well plates containing 2 ml of medium/well
and incubated for 48 h at 37 °C. Confluent cells were selected
over 9 days by initially passaging 2 wells into a 10-cm dish. After
cell attachment, 3 g/ml puromycin was included in the
Human p14-ARF Tumor Suppressor Promotes MAGE-A11 Degradation
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 25175
medium that was exchanged every 2 or 3 days. LAPC-4 or HeLa
cells not treated with retrovirus were killed within 5 days of
treatment with 3 g/ml puromycin. Quantitative RT-PCR of
RNA extracted using TRIzol from LAPC-4 and HeLa pBabe-
control and pBabe-ARF-expressing cells was performed using
sequence specific primers for MAGE-A11 and peptidylprolyl
isomerase A control as described (38).
Lentivirus shRNA—Endogenous ARF expression was inhib-
ited using a pLK01-modified lentiviral vector that contains an
RNA polymerase III-shRNA expression cassette and a puromy-
cin resistance gene under the control of the phosphoglycerate
kinase promoter. ARF shRNA targeted the 5-CTCGTGCT-
GATGCTACTGAgg-3 sense sequence in the unique ARF
exon 1B (antisense sequence ccTCAGTAGCATCAGCAC-
GAG-3). Lentiviral vectors carrying nonspecific shRNA or
empty vector with no shRNA served as negative controls. Vec-
tor particles (106 IU/ml) were generated by a three-plasmid
transfection in HEK293 cells (39). HeLa cells (3  105 cells/well
in 6-well plates) were transduced using 0.1 or 0.25 ml of vector-
containing conditioned media for 48 h at 37 °C and selected for
puromycin resistance over several days in the presence of 3
g/ml puromycin.
Immunochemistry—Immunoblot analysis was performed on
cell extracts prepared in lysis buffer that contained 1% Triton
X-100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 2 mM
EDTA, 0.05 mM NaF, 2 mM sodium vanadate, 50 mM Tris-HCl,
pH 7.5, 1 mM DTT, 1 mM PMSF, and complete protease inhib-
itors (Roche Applied Science). Immunoprecipitation experi-
ments were performed by extracting cells in lysis buffer that
contained 1% Triton X-100, 0.5% deoxycholate, 0.15 M NaCl,
0.05 M NaF, 1 mM EDTA, 50 mM Tris-HCl, 1 mM DTT, 1 mM
PMSF, and complete protease inhibitors and processed as
described (5).
Immunoblots of 10 or 12% acrylamide gels containing SDS
were probed using the following antibodies: MAGE1 or
MAGE2 rabbit polyclonal antibody against baculovirus ex-
pressed FLAG-tagged human MAGE-A11 (0.5–10 g/ml) (5);
rabbit polyclonal anti-VP16 tag ab4809 antibody (1:500 dilu-
tion, Abcam); rabbit polyclonal human p14-ARF 10437 anti-
body provided by W. G. Yarbrough (1:200 dilution); rabbit
polyclonal AR32 antibody against a human AR NH2-terminal
peptide (1–3 g/ml) (40); rabbit polyclonal human p300 anti-
body sc-585 (1:200 dilution, Santa Cruz Biotechnology); rabbit
polyclonal E2F1 antibody sc-193 (1:200 dilution, Santa Cruz
Biotechnology); HA tag 12ca5 mouse monoclonal antibody
(University of North Carolina Antibody Core Facility, 1–2
g/ml); anti-FLAG M2 F3165 mouse monoclonal antibody
(1:200 dilution, Sigma); anti-GAL4 DNA-binding domain rab-
bit polyclonal sc-577 antibody (1:500 dilution, Santa Cruz
Biotechnology); mouse monoclonal p27Kip1 610241 antibody
(1:200 dilution, BD Biosciences); and -actin ab6276 mouse
antibody (1:5000 dilution, Abcam). Immunoblots were cali-
brated using dual color Precision Plus protein standards (Bio-
Rad). Immunoreactivity was detected by chemiluminescence
using SuperSignal West Dura extended duration substrate
(Pierce). Protein bands were quantitated using ImageQuant TL
Software (GE Healthcare Life Sciences).
Cell Growth Assays—LAPC-4 cell growth assays were per-
formed using cells that stably express retrovirus derived from
pBabe-puro control or pBabe-puro-hARF retroviral vectors.
LAPC4 control and LAPC-4-ARF cells were plated in triplicate
(4  105 cells/well) in 24-well plates with 0.5 ml of phenol red-
free growth medium containing 10% charcoal-stripped serum
(Atlanta Biologicals). The next day 0.1 ml of phenol red-free,
serum-free medium without DHT was added or with DHT for a
final concentration of 1 nM DHT. Cells were retreated with or
without 1 nM DHT after 72 h on day 3. Plates were aspirated
24 h after addition of DHT and daily thereafter. Serum-free
medium (0.2 ml) and 20 l of Cell Counting Kit-8 reagent
(Dojindo Laboratories) were added/well and incubated at 37 °C
for 2.5 h. Optical absorbance was determined at 485 nm. Statis-
tical significance was determined using two-way ANOVA.
Results
Interaction with Human ARF Promotes the Degradation of
MAGE-A11—MAGE-A11 coregulator activity depends on
interactions with the ligand-activated human AR and p300
transcriptional coactivator (1, 6, 10, 11). MAGE-A11 also inter-
acts with and increases the transcriptional activity of the E2F1
oncoprotein that promotes cell cycle progression through
interactions with p107 of the retinoblastoma family (5). Based
on the ability of MAGE-A11 to stabilize and increase E2F1 tran-
scriptional activity, and the ARF tumor suppressor to promote
E2F1 degradation and inhibit E2F1 transcriptional activity (41,
42), we investigated whether MAGE-A11 is a direct target of
human ARF or proteins regulated by ARF.
Interaction between MAGE-A11 and ARF was demon-
strated by the coimmunoprecipitation of HA-ARF with FLAG-
MAGE (Fig. 1A), and by MAGE-A11 coimmunoprecipitation
with FLAG-ARF (Fig. 1B). There was no evidence for nonspe-
cific association of ARF or MAGE-A11 with the FLAG antibody
resin. However, expression of ARF decreased MAGE-A11 lev-
els in cell extracts by 86% (Fig. 1A) or 44% (Fig. 1B) when nor-
malized to the -actin protein loading control.
An interaction between MAGE-A11 and ARF was also evi-
dent in a mammalian two-hybrid assay. Activity of a luciferase
reporter gene linked to GAL4 DNA binding sites was increased
by 6-fold with the coexpression of an ARF-GAL4 DNA-binding
domain fusion protein and a full-length MAGE-A11-VP16 acti-
vation domain fusion protein (Fig. 1C). The similar activity
induced by GAL-ARF in the presence of full-length 1– 429-
amino acid VP-MAGE or VP-MAGE-(112– 429) suggested that
ARF interacts with a COOH-terminal region of MAGE-A11.
This was consistent with a weak two-hybrid interaction be-
tween GAL-ARF and VP-MAGE-(2–110) that contains only
the MAGE-A11 NH2-terminal region or between GAL-ARF
and VP-MAGE-(112–362) that contained the central region of
MAGE-A11. GAL-ARF, VP-MAGE, and VP-MAGE fragments
expressed at similar levels, except for VP-MAGE-(2–110),
which was expressed at a lower level (Fig. 1D). The results sug-
gest an interaction between MAGE-A11 and ARF requires the
COOH-terminal region of MAGE-A11.
The decline in MAGE-A11 associated with ARF expression
(Fig. 1, A and B) suggested that ARF increases the degradation
of MAGE-A11. This was supported by a dose-dependent
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inverse relationship between ARF and MAGE-A11 relative to
-actin (Fig. 2A). In contrast, there was a direct relationship
between ARF and AR (Fig. 2B) that was lost with expression of
MAGE-A11 (Fig. 2C). When expressed together, the levels of
both AR and MAGE-A11 decreased with increasing ARF. The
results suggest that the susceptibility of MAGE-A11 to degra-
dation promoted by ARF was extended to AR through the inter-
action between AR and MAGE-A11.
Inhibition of protein synthesis using cycloheximide provided
additional evidence that ARF increases the degradation rate of
MAGE-A11 (Fig. 2D). The intracellular half-life of MAGE-A11
decreased from 8 to 4 h with the expression of ARF.
The region in MAGE-A11 required for degradation pro-
moted by ARF was investigated based on the similar suscepti-
bility of MAGE-A11 (Fig. 2A) and a full-length GAL-MAGE
fusion protein (Fig. 2E, lanes 1 and 2) to degradation promoted
by ARF. The stability of GAL-MAGE-(2–121) or GAL-MAGE-
(2–205) in the presence of ARF (Fig. 2E, lanes 3– 6) provided
further evidence that the MAGE-A11 COOH-terminal region
is targeted for degradation by ARF. In contrast, GAL-MAGE-
(112– 429) and GAL-MAGE-(112–276), which share the cen-
tral region of MAGE-A11, were down-regulated by ARF similar
to full-length GAL-MAGE (Fig. 2F).
The results show that ARF promotes the degradation of
MAGE-A11 independent of the MAGE-A11 NH-terminal
region or AR. Increased degradation of AR promoted by ARF
was evident only in the presence of MAGE-A11.
MAGE-A11 Degradation by the Proteasome Promoted by
Human ARF Independent of Ubiquitination—Dependence on
the proteasome and lysine ubiquitination for MAGE-A11 deg-
radation promoted by ARF was investigated using chemical
inhibitors and alanine substitution mutants. MAGE-A11 levels
in the presence of ARF and normalized to -actin increased
1.3-fold after incubation with 1 M MG132 and 2.7-fold with 10
M MG132 (Fig. 3A). A similar increase in MAGE-A11 was
seen in the presence of ARF and 5 M bortezomib, another
proteasome inhibitor (43) (Fig. 3B). The results provided evi-
dence that ARF promotes MAGE-A11 degradation by the
proteasome.
The requirement for lysine ubiquitination in the proteasomal
degradation of MAGE-A11 promoted by ARF was examined by
first establishing a minimal region of MAGE-A11 that could be
subjected to lysine mutagenesis. In agreement with results in
Fig. 2 (E and F), the MAGE-(2–252) NH2-terminal fragment did
not interact with FLAG-ARF (Fig. 3C, lanes 4 and 11). This was
in contrast to a strong interaction between ARF and MAGE-
(112– 429) and MAGE-(112–362) and a weaker interaction
with MAGE-(112–276) (Fig. 3C, lanes 5–7 and 12–14).
Because MAGE-(112–276) interacted with ARF (Fig. 3C) and
was down-regulated by ARF (Fig. 2F), we constructed MAGE-
(112–276)-7KA, in which all 7 lysine residues in this fragment
(Lys at positions 121, 202, 225, 236, 240, 245, and 254) were
substituted simultaneously with alanine (9). Some of these
lysine residues (Lys240 and Lys245) were implicated previously
FIGURE 1. MAGE-A11 interaction with ARF. A, immunoprecipitation of ARF was performed in COS1 cells using 5 g of pCMV-FLAG or 5 g of pCMV-FLAG-
MAGE with or without 6 g of pCI-neo-HA-ARF/10-cm dish. Cell extracts (80 g of protein/lane, left panel) and immunoprecipitates (IP, right panel) were probed
using FLAG-M2, HA, and -actin antibodies. MAGE-A11 versus -actin band intensity in cell extracts is shown in the lower panel. B, immunoprecipitation of
MAGE-A11 was performed in COS1 cells using 6 g of pCMV-FLAG or 6 g of FLAG-ARF with or without 3 g of pSG5-MAGE/10-cm dish. Extracts (60 g of
protein/lane, left panel) and immunoprecipitates (IP, right panel) from cells treated with 5 ng/ml EGF for 24 h before harvest were probed using FLAG-M2,
MAGE2, and -actin antibodies. MAGE-A11 versus -actin band intensity in cell extracts is shown in the lower panel. C, mammalian two-hybrid assay demon-
strating MAGE-A11 interaction with ARF was performed in HeLa cells by expressing 0.1 g of 5XGAL4Luc3 with 50 ng of GAL-ARF and 50 ng of pVP16 (),
full-length VP-MAGE-(2– 429), or VP-MAGE-(2–110), 112– 429, or 112–362. D, expression levels were compared by expressing per 6-cm COS1 cell dish 6 g of
VP16 empty vector (lane 1), VP-MAGE-(2– 429), 112– 429, 112–362 or 2–110 (lanes 2–5), GAL-O empty vector (lane 6), or GAL-ARF (lane 7). Cells were incubated
with 1 M MG132 for 24 h prior to harvest. Cell extracts (70 g of protein/lane) were probed on an immunoblot using VP16 and GAL4 antibodies. A nonspecific
(NS) VP16 antibody immunoreactive band of 72 kDa migrated similar to VP-MAGE-(2– 429).
Human p14-ARF Tumor Suppressor Promotes MAGE-A11 Degradation
OCTOBER 9, 2015 • VOLUME 290 • NUMBER 41 JOURNAL OF BIOLOGICAL CHEMISTRY 25177
as sites of monoubiquitination required for MAGE-A11 to
interact with AR (9). The similar decline in MAGE-(112–276)
and MAGE-(112–276)-7KA in the presence of ARF (Fig. 3D)
provided evidence that lysine ubiquitination is not required for
the proteasomal degradation of MAGE-A11 promoted by ARF.
The difference in migration between MAGE-(112–276) and
7KA mutant was attributed to neutralization of multiple
charged lysine residues by alanine substitution. Site-directed
mutagenesis at hydrophobic residues Val252, Ile253, Leu274,
Phe260, Phe264, or Phe275; charged residue Arg235; or multiple
lysines did not diminish MAGE-112–276 interaction with ARF.
The results suggest that the interaction between ARF and the
central region of MAGE-A11 involves multiple domains that
result in degradation by the proteasome independent of lysine
ubiquitination. The ability of ARF to promote proteasomal deg-
radation of MAGE-A11 is consistent with tumor suppressor of
ARF that inhibits the cell growth promoting properties of
MAGE-A11.
Inverse Relationship between Endogenous ARF and MAGE-
A11—An increase in MAGE-A11 degradation promoted by
ARF should decrease endogenous MAGE-A11 levels in normal
cells that have higher levels of ARF. Similarly, higher levels of
endogenous MAGE-A11 in prostate cancer cells may be asso-
ciated with low levels of ARF to promote the growth of castra-
tion-resistant prostate cancer. We therefore investigated the
relative levels of endogenous MAGE-A11 and ARF.
ARF was not easy to detect in LAPC-4 prostate cancer cells
that have relatively high levels of MAGE-A1 using human ARF
and MAGE-A11-specific antibodies (Fig. 4A, lane 4) (2, 5).
However, a weak band corresponding to ARF could be detected
with overexposure of the blot (not shown), which indicated a
low level of ARF in LAPC-4 cells. An inverse relationship
FIGURE 2. ARF promotes MAGE-A11 degradation. A, inverse relationship between MAGE-A11 and ARF was demonstrated by expressing 2 g of pSG5 (lane
1) or 2 g of pSG5-MAGE with 0.01–2 g of pCI-neo-HA-ARF/two 6-cm CV1 cell dishes (lanes 2–9). Cell extracts (80 g of protein/lane) pooled from two 6-cm
dishes were analyzed on an immunoblot using MAGE1, HA, and -actin antibodies. B, increase in AR and ARF was shown by expressing 2 g of pCMV5 (lane 1)
or 2 g of pCMV-AR with 0.01–2 g of pCI-neo-HA-ARF balanced with up to 2 g of pCMV5 (lane 2–9)/two 6-cm CV1 cell dishes. Cell extracts (80 g of
protein/lane) from two pooled 6-cm dishes were probed on an immunoblot using AR32, HA tag, and -actin antibodies. C, that ARF promotes AR degradation
in the presence of MAGE-A11 was shown by expressing 2 g of pSG5 (lane 1) or 2 g of pSG5-MAGE with 1 g of pCMV-AR and 0.01–2 g of pCI-neo-HA-ARF/
two 6-cm CV1 cell dishes (lanes 2–9). Cell extracts (80 g of protein/lane) pooled from two 6-cm dishes were analyzed on an immunoblot using AR32, MAGE1,
HA, and -actin antibodies. D, increase in MAGE-A11 degradation in the presence of ARF was shown by expressing 1 g of pSG5-MAGE with or without 0.5 g
of pCI-neo-HA-ARF/6-cm COS1 cell dish. The day after transfection, cells were incubated for 24 h in serum-free medium and then in fresh serum-free medium
containing 10 g/ml cycloheximide for 0, 2, 4, 8, and 24 h. Cell extracts (40 g of protein/lane) were probed on an immunoblot using MAGE1, HA, and -actin
antibodies. E, region of MAGE-A11 required for degradation promoted by ARF was determined by expressing 5 g of full-length GAL-MAGE-(2– 429) or
GAL-MAGE-(2–121) or 2–205 with or without 2 g of pCI-neo-HA-ARF/6-cm COS1 cell dish. Cell extracts (60 g of protein/lane) were probed on an immunoblot
using GAL4 DNA-binding domain, HA, and -actin antibodies. F, susceptibility of GAL-MAGE fragments to degradation promoted by ARF was tested by
expressing 6 g of GAL-O (lane 1), GAL-MAGE-(2– 429) (lanes 2 and 3), 112– 429 (lanes 4 and 5), or 112–276 (lanes 6 and 7) with or without 2 g of pCI-neo-HA-
ARF or pCI-neo-HA-ARF alone (lane 8) in 6-cm COS cell dishes. Cells were incubated with 1 M MG132 for 20 h prior to harvest to increase detection of
GAL-MAGE fragments. Cell extracts (80 g of protein/lane) were probed on immunoblots using GAL DNA-binding domain, HA and -actin antibodies.
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between MAGE-A11 and ARF was also suggested by relatively
low levels of MAGE-A11 and higher levels of ARF in human
cervical carcinoma HeLa cells compared with LAPC-4 cells
(Fig. 4A, lanes 3 and 4). ARF and MAGE-A11 were not detected
in COS1 or CV1 cells (Fig. 4A, lanes 1 and 2), although endog-
enous MAGE-A11 can be detected in COS1 cells in a cell cycle-
dependent manner (10).
PC-3 and DU145 prostate cancer cells had higher levels of
ARF (Fig. 4B, lanes 5 and 6) (44, 45), and MAGE-A11 was not
detected, consistent with ARF promoting the degradation of
MAGE-A11. Low levels of MAGE-A11 in PC-3 and DU145
cells also result from CpG dinucleotide DNA methylation at the
MAGE-A11 gene promoter transcription start site (2). LNCaP,
CWR-R1, and 22Rv1 prostate cancer cells had intermediate lev-
els of ARF relative to LAPC-4, PC-3, and DU145 cells, and
MAGE-A11 was difficult to detect (Fig. 4B).
The cyclin-dependent kinase inhibitor and tumor suppressor
p27Kip1 is down-regulated by MAGE-A11 in LAPC-4 cells (5).
Accordingly, p27Kip1 was almost undetectable in LAPC-4 and
was not detected in PC-3 or DU145 cells (Fig. 4B). A similar
intermediate level of p27Kip1 in CWR-R1 and LNCaP cells was
less than 22Rv1 cells.
The results demonstrate that higher levels of MAGE-A11 are
associated with low levels of ARF in support of ARF promoting
the degradation of MAGE-A11. The results provide further evi-
dence that MAGE-A11 contributes to low levels of p27Kip1 and
that p27Kip1 may be down-regulated by ARF independent of
MAGE-A11.
Down-regulation of MAGE-A11 by ARF—To address further
a possible inverse relationship between MAGE-A11 and ARF,
FIGURE 3. Degradation of MAGE-A11 promoted by ARF mediated by the proteasome. A, proteasomal degradation of MAGE-A11 promoted by ARF was
shown by expressing 2 g of pSG5 (lane 1) or 2 g of pSG5-MAGE with or without 2 g of pCI-neo-HA-ARF/6-cm COS1 cell dish treated for 2 h prior to harvest
without (lanes 2 and 3) or with 1 M MG132 (lanes 4 and 5) or 10 M MG132 (lanes 6 and 7). The immunoblot of cell extracts (40 g of protein/lane) was probed
using MAGE1, HA, and -actin antibodies. MAGE-A11 versus -actin band intensity is shown in the lower panel. B, proteasomal degradation of MAGE-A11
promoted by ARF was tested by expressing 2 g of pSG5 (lane 1) or 2 g of pSG5-MAGE with or without 0.5 g of pCI-neo-HA-ARF/6-cm COS1 cell dish treated
for 4 h prior to harvest without (lanes 2 and 3) or with 5 M bortezomib (LC Laboratories) (lanes 4 and 5). The immunoblot of cell extracts (80 g of protein/lane)
was probed using MAGE1, HA, and -actin antibodies. C, coimmunoprecipitation of HA-MAGE fragments with FLAG-ARF was performed in COS1 cells by
expressing 6 g of FLAG empty vector or 6 g of FLAG-ARF with 6 g of pSG5-HA-MAGE-(2– 429), 3 g of pSG5-HA-MAGE-(2–252), 3 g of pSG5-HA-MAGE-
(112– 429), 5 g of pSG5-HA-MAGE-(112–362), or 6 g of pSG5-HA-MAGE-(112–276). Cells were incubated for 24 h prior to harvest with 5 ng/ml EGF and 1 M
MG132. Cell extracts (60 g of protein/lane) and immunoprecipitates were probed on the immunoblot using FLAG-M2, HA, and -actin antibodies. D,
independence of lysine ubiquitination for MAGE-A11 degradation promoted by ARF was demonstrated by expressing 6 g of pSG5 (lane 1), pSG5-HA-MAGE-
(112–276) WT (lanes 2 and 3), or pSG5-HA-MAGE-(112–276)-7KA with K121A,K202A,K225A,K236A,K240A,K245A,K254A mutations (lanes 4 and 5) with or
without 2 g of pCI-neo-HA-ARF/COS1 cell 6-cm dish. Cell extracts (40 g of protein/lane) were probed on the immunoblot using HA and -actin antibodies.
FIGURE 4. Endogenous MAGE-A11 and ARF in cancer cells. A, relative
MAGE-A11 and ARF protein levels were compared in COS1, CV1, HeLa, and
LAPC-4 cell extracts (80 g of protein/lane) on immunoblots probed using
MAGE1, ARF, and -actin antibodies. B, relative MAGE-A11, ARF and p27Kip1
protein levels in LAPC-4 (LA), CWR-R1 (CW), LNCaP (LN), 22Rv1 (RV), PC-3 (PC),
and DU145 (DU) cell extracts (60 g of protein/lane) probed using MAGE1,
ARF, p27Kip1, and -actin antibodies.
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retrovirus derived from pBabe-control and pBabe-ARF vectors
were used for stable expression of ARF in HeLa and LAPC-4
cells selected using puromycin. A 3-fold or greater increase in
ARF decreased endogenous MAGE-A11 levels by 64% in HeLa
cells (Fig. 5A) and by 45% in LAPC-4 cells (Fig. 5B) relative to
control cells and normalized to the -actin protein loading con-
trol. Quantitative RT-PCR analysis of MAGE-A11 mRNA
extracted from LAPC-4 and HeLa pBabe-control or pBabe-
ARF expressing cells using MAGE-A11 and peptidylprolyl
isomerase A control specific primers (38) showed no significant
change in MAGE-A11 mRNA with the expression of ARF (Fig.
5C). The results demonstrate that lower levels of MAGE-A11
are associated with higher levels of ARF in support of an inverse
relationship between MAGE-A11 and ARF consistent with
MAGE-A11 degradation promoted by ARF.
We next determined whether stable retrovirus expression of
ARF alters the growth of LAPC-4 cells in the absence or pres-
ence of androgen. DHT increased the growth of LAPC-4
pBabe-control cells analyzed using a colorimetric cell counting
assay (Fig. 5D). However, stable expression of ARF inhibited
LAPC-4 cell growth over 5 days in the absence or presence of 1
nM DHT.
An increase in MAGE-A11 degradation promoted by ARF
would suggest that knockdown of ARF might increase endoge-
nous levels of MAGE-A11. This was explored in HeLa cells that
express low levels of MAGE-A11 and higher levels of ARF rel-
ative to LAPC-4 cells. Lentivirus-expressed shRNA that targets
the unique exon 1B region of the ARF gene decreased ARF
levels and increased the levels of MAGE-A11 in HeLa cells
treated without (Fig. 6A) or with the proteasome inhibitor,
MG132 (Fig. 6B).
The results suggest that the low abundance MAGE-A11 reg-
ulatory protein is inversely regulated to ARF. Increased degra-
dation of MAGE-A11 promoted by ARF was associated with
inhibition of prostate cancer cell growth.
Inhibition of AR Transcriptional Activity by Human ARF—
The inhibitory effect of ARF on coregulator activity of MAGE-
A11 was investigated by measuring AR transcriptional activity
that is increased by MAGE-A11 (1). AR transactivation of the
prostate-specific antigen enhancer linked to a luciferase
reporter gene was inhibited by ARF (Fig. 7A) in agreement with
a previous report (46). ARF also blocked the stimulatory effect
of MAGE-A11 on androgen-dependent AR transcriptional
activity. The results suggest that an inhibitory effect of ARF on
AR transcriptional activity is mediated by negative regulation of
MAGE-A11.
Inhibition by ARF of the MAGE-A11-induced increase in AR
transactivation suggested that the interaction between AR and
MAGE-A11 does not protect against degradation promoted by
ARF. This was suggested earlier (Fig. 2) where susceptibility of
MAGE-A11 to degradation promoted by ARF was extended to
AR. ARF also inhibited the stabilization of MAGE-A11 in the
FIGURE 5. Down-regulation of endogenous MAGE-A11 by ARF. A, down-regulation of MAGE-A11 in HeLa cells by ARF was shown using untransduced HeLa
cells (lane 1), HeLa cells transduced with 0.25 ml of pBabe-puro control retrovirus/well of a 6-well plate (lane 2), or pBabe-puro-hARF retrovirus for stable
expression of human ARF (lane 3). Retrovirus transduced cells were selected using 3 g/ml puromycin as described under “Experimental Procedures.” Cell
extracts (60 g of protein/lane) were probed on the immunoblot using MAGE1 (10 g/ml), human p14-ARF 10437 (1:500 dilution), and -actin antibodies.
MAGE-A11 versus -actin band intensity is shown in the right panel. B, down-regulation of MAGE-A11 in LAPC-4 cells by ARF was shown using untransduced
LAPC-4 cells (lane 1), LAPC-4 cells transduced with 0.25 ml pBabe-puro-derived control retrovirus/well of a 6-well plate (lane 2), or pBabe-puro-hARF retrovirus
for stable expression of human ARF (lane 3). Retrovirus transduced LAPC-4 cells were selected using 3 g/ml puromycin as described under “Experimental
Procedures.” Cell extracts (60 g of protein/lane) were probed on the immunoblot using MAGE1 (10 g/ml), human p14-ARF 10437 (1:500 dilution), and
-actin antibodies. MAGE-A11 versus -actin band intensity is shown in the right panel. C, quantitative RT-PCR was performed on RNA extracted from LAPC-4
or HeLa pBabe-control or pBabe-ARF expressing cells using specific amplification primers and shown for MAGE-A11 relative to the peptidylprolyl isomerase A
control. D, increased ARF expression slows LAPC-4 cell growth was shown using LAPC-4 cells transduced with retrovirus as described in B. The day after plating,
cells were incubated with or without 1 nM DHT and quantitated daily using a colorimetric assay as described under “Experimental Procedures.” Statistical
significance between LAPC-4 pBabe and pBabe-ARF cells was observed in the absence or presence of 1 nM DHT based on two-way ANOVA (p  0.001).
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presence of AR (Fig. 7B, lanes 3– 6) and interfered with the
increase in AR levels in the presence of MAGE-A11 (Fig. 7B,
lanes 2– 4). Reciprocal stabilization between AR and MAGE-
A11 in the absence or presence of androgen only partially res-
cued MAGE-A11 from degradation promoted by ARF (Fig. 7C).
A similar analysis was performed on the constitutive activity
of AR-(1– 660) NH2-terminal and DNA-binding fragment that
lacks the ligand binding domain and mimics AR splice variants
reported in prostate cancer (47– 49). ARF inhibited the consti-
tutive activity of AR-(1– 660) with or without expression of
MAGE-A11 (Fig. 8A, left bars). However, constitutive activity
of AR-(1– 660)-L26A,F27A, in which the AR NH2-terminal
FXXLF motif interaction site for MAGE-A11 was mutated (1),
showed little stimulation by MAGE-A11 or inhibition by ARF
(Fig. 8A, right bars).
The increase in AR-(1– 660) constitutive activity in the pres-
ence of MAGE-A11 was associated with reciprocal stabilization
between AR-(1– 660) and MAGE-A11 (Fig. 8, B and C) similar
to that seen with full-length AR. The increase in AR-(1– 660)
levels associated with MAGE-A11 was blocked by ARF, and
MAGE-A11 interaction with AR-(1– 660) only partially res-
cued MAGE-A11 from degradation promoted by ARF. The
absence of a stabilizing effect of MAGE-A11 on AR-(1– 660)-
L26A,F27A (Fig. 8C) demonstrated reciprocal stabilization
between AR and MAGE-A11 depended on MAGE-A11 bind-
ing the AR NH2-terminal FXXLF motif.
The results suggest that ARF interferes with MAGE-A11-
induced AR stabilization and increased transcriptional activity
of AR or a splice variant-like form of AR. MAGE-A11 remained
susceptible to degradation promoted by ARF independent of its
interaction with AR.
Human ARF Inhibits the MAGE-A11-induced Increase in
E2F1 Transcriptional Activity—MAGE-A11 interacts with, sta-
bilizes, and increases the transcriptional activity of E2F1, a tran-
scription factor that promotes progression through the cell
cycle (5). In contrast, ARF interacts with and inhibits E2F1 tran-
scriptional activity through unknown mechanisms (42). We
therefore determined whether ARF blocks the stabilization of
E2F1 by MAGE-A11 or the MAGE-A11-dependent increase in
endogenous E2F1 transcriptional activity.
The increase in E2F1 levels associated with MAGE-A11 was
partially inhibited by ARF (Fig. 9A, lanes 4 – 6). This did not
appear to result simply from increased degradation of MAGE-
A11 promoted by ARF. MAGE-A11 levels declined to a greater
extent with ARF expression than with E2F1 stabilization (Fig.
9A, lanes 2–5). However, ARF did not decrease MAGE-A11
levels further in the presence of E2F1, and ARF did not promote
the degradation of E2F1, in agreement and in contrast to previ-
ous reports (41, 51).
Immunoprecipitation studies addressed whether the inhibi-
tory effects of ARF on E2F1 stabilization by MAGE-A11 might
result from ARF interference with MAGE-A11 interaction with
E2F1. MAGE-A11 and ARF were each associated with FLAG-
E2F1 (Fig. 9B, lanes 5 and 6). However, when expressed
together, ARF inhibited the interaction between MAGE-A11
and E2F1 to a greater extent than could be accounted for by the
lower levels of MAGE-A11 in the presence of ARF (Fig. 9B, lane
7). ARF also blocked the dose-dependent stimulatory effect of
MAGE-A11 on endogenous E2F1 transcriptional activity when
assayed in the absence or presence of p300 (Fig. 9C). There was
a dose-dependent decrease in MAGE-A11-induced endoge-
nous E2F1 transcriptional activity with increasing expression of
ARF (Fig. 9D). Specificity for transcriptional repression by ARF
was suggested by the absence of inhibition by ARF of CMV-Luc
or pSG5-Luc constitutive transcriptional activity (not shown).
The results suggest that ARF interferes with the stabilizing
and transcriptional enhancing effects of MAGE-A11 on E2F1
by blocking MAGE-A11 interaction with E2F1 and by promot-
ing MAGE-A11 degradation. Inhibition of the stimulatory
effects of MAGE-A11 on E2F1 transcriptional activity is con-
sistent with the tumor suppressor activity of ARF.
Effects of MAGE-A11 on HDM2 Stabilization and E2F1
Transcriptional Activity—A well known function of ARF that
contributes to cell cycle arrest is the inhibition of HDM2 E3
ubiquitin ligase activity, which results in up-regulation of p53 to
promote cell cycle arrest or apoptosis (23–27, 52) and down-
regulation of E2F1 activation of genes involved in cell cycle
progression (53–55). This suggests that one mechanism by
which cancer cells interfere with the tumor suppressor activity
of ARF is through the stabilization of HDM2.
We found that MAGE-A11 increased the levels of 90-kDa
HDM2 by 15-fold detected on an 8% acrylamide gel and an
up-shifted self-ubiquitinated or sumoylated form of HDM2 (56,
57) when normalized to the -actin protein loading control
(Fig. 10A). Stabilization of 100-kDa HDM2 by MAGE-A11 on
a 12% acrylamide gel was also increased in the presence of ARF
(Fig. 10B, lanes 2–5), even though ARF promoted the degrada-
tion of MAGE-A11 in the absence or presence of HDM2 (Fig.
10B, lanes 5–7). The small increase in HDM2 by ARF (Fig. 10B,
lanes 2 and 4) was in agreement with a previous report that ARF
increases the steady-state levels of HDM2 (58). Although stabi-
lization of HDM2 by MAGE-A11 was inhibited by E2F1 (Fig.
10C, lanes 5 and 7), there was no evidence that HDM2 altered
FIGURE 6. Lentivirus shRNA knockdown of ARF increases MAGE-A11 lev-
els. HeLa cells in 6-well plates were untransduced () or transduced with
nonspecific control lentivirus shRNA for empty shRNA (NS1), 18-bp scrambled
lentivirus nonspecific control-2 (NS2), or 100 or 250 l of lentivirus ARF shRNA
that targets exon 1B of the ARF gene. Cells were selected using 3 g/ml
puromycin and incubated (A) without or (B) with 1 M MG132 proteasome
inhibitor 20 h prior to harvest. Immunoblots of cell extracts (60 g of protein/
lane) were probed using FLAG-MAGE1, ARF, and -actin antibodies. MAGE-
A11 to -actin relative band intensity is shown on the right.
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E2F1 levels, and HDM2 did not interfere with E2F1 stabiliza-
tion by MAGE-A11 (Fig. 10C, lanes 2–5).
The increase in HDM2 caused by MAGE-A11 (Fig. 10A) and
the ability of MAGE-A11 or HDM2 to increase E2F1 transcrip-
tional activity (5, 53–55) suggested that MAGE-A11 and
HDM2 may cooperate to up-regulate E2F1 transcriptional
activity. This was supported by a similar increase in endoge-
nous E2F1 transactivation in response to HDM2 or MAGE-A11
that was nearly additive when expressed together (Fig. 10D).
MAGE-A11 and HDM2 functioned cooperatively with p300 to
up-regulate endogenous E2F1 transcriptional activity, which
reflects the ability of MAGE-A11 and HDM2 to interact with
p300 during gene transcription (5, 10, 59). The increase in E2F1
transcriptional activity in response to MAGE-A11 and p300
was greater with HDM2 and inhibited by ARF with or without
HDM2 (Fig. 10E). Cooperation between MAGE-A11, HDM2,
and p300 in the up-regulation of E2F1 transcriptional activity
suggested that p300 might influence HDM2 levels. However,
unlike MAGE-A11, which stabilized HDM2 (Fig. 10F, lanes 2
and 3), p300 did not increase HDM2 or interfere with HDM2
stabilization in the presence of MAGE-A11 (Fig. 10F, lanes
3–5).
The results suggest that MAGE-A11 cooperates with HDM2
and p300 to up-regulate E2F1 transcriptional activity. MAGE-
A11 in a complex with HDM2 and ARF may interfere with
HDM2 inactivation by ARF.
Discussion
Post-translational Down-regulation of MAGE-A11 by Hu-
man ARF Tumor Suppressor—MAGE-A11 is a multifunctional
protein involved in the regulation of cell cycle proteins. The
evolution of the MAGE-A11 among primates, its increased
expression during androgen deprivation therapy of prostate
cancer, its function as an AR coregulator, and the requirement
for MAGE-A11 in prostate cancer cell growth support the con-
cept that MAGE-A11 is a proto-oncogene that hyperactivates
human AR and promotes the development of castration-resis-
tant prostate cancer (38). One mechanism for the increase in
MAGE-A11 in prostate cancer clinical samples during andro-
gen deprivation therapy and in the CWR22 human xenograft
FIGURE 7. ARF inhibition of androgen-dependent AR transcriptional activity and reciprocal AR and MAGE-A11 stabilization did not protect MAGE-A11
from degradation promoted by ARF. A, AR transcriptional activity was assayed in 12-well CV1 cell plates using 0.25 g of PSA-Enh-Luc and 25 ng of pCMV-AR
with 50 ng of pSG5 or 25 ng of pCI-neo-HA-ARF and 50 ng of pSG5-MAGE alone or together. The cells were incubated for 24 h with or without 10 nM DHT. B,
immunoblot showing AR does not protect MAGE-A11 against degradation promoted by ARF was performed in 10-cm CV1 cell dishes by expressing 2 g of
pCMV5 (lane 1) or 2 g of pCMV-AR (lane 2) with 1 g of pSG5-MAGE (lane 3), 2 g of pCI-neo-HA-ARF (lane 4), or pSG5-MAGE and pCI-neo-HA-ARF together
(lane 5). pSG5-MAGE (1 g, lane 6) or 2 g of pCI-neo-HA-ARF was expressed alone (lane 7) or together (lane 8). The immunoblot of cell extracts (80 g of
protein/lane) was probed using AR32, MAGE1, HA, and -actin antibodies. C, androgen dependence of AR and ARF effects on MAGE-A11 was performed using
pCMV5 (lane 1) or pCMV-AR alone with or without 10 nM DHT (lanes 2 and 3) or pCMV-AR with pSG5-MAGE with or without 10 nM DHT (lanes 4 and 5),
pCI-neo-HA-ARF with or without 10 nM DHT (lanes 6 and 7), pSG5-MAGE and pCI-neo-HA-ARF with or without 10 nM DHT (lanes 8 and 9), pSG5-MAGE (lane
10), pCI-neo-HA-ARF (lane 11), or pSG5-MAGE and pCI-neo-HA-ARF (lane 12) in CV1 cells as described and probed in B.
FIGURE 8. Inhibition of AR-(1– 660) constitutive activity by ARF. A, effect of ARF on constitutive activity of AR-(1– 660) and AR-(1– 660)-FXXAA was deter-
mined in 12-well CV1 cell plates by expressing 0.25 g of PSA-Enh-Luc with 25 ng of pCMV5 (), pCMV-AR-(1– 660) or pCMV-AR-(1– 660)-L26A,F27A with 50 ng
of pSG5 (), 50 ng of pSG5-MAGE, or 25 ng of pCI-neo-HA-ARF alone or together. B, ARF inhibition of AR-(1– 660) stabilization by MAGE-A11 was shown on an
immunoblot by expressing 2 g of pCMV5 (lane 1) or 2 g of pCMV-AR-(1– 660) alone (lane 2) or with 1 g of pSG5-MAGE (lane 3), 2 g of pCI-neo-HA-ARF (lane
4), or pSG5-MAGE and pCI-neo-HA-ARF together (lane 5) per 10-cm CV1 cell dish. The immunoblot of cell extracts (80 g of protein/lane) was probed using
AR32, MAGE1, HA, and -actin antibodies. C, ARF inhibition of AR-(1– 660) stabilization by MAGE-A11 is shown on an immunoblot of AR-(1– 660) or AR-(1–
660)-L26A,F27A mutant, MAGE-A11, and ARF performed in CV1 cells and probed as in B.
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model of prostate cancer that undergoes remission after castra-
tion but regrows after castration is progressive hypomethyla-
tion of CpG dinucleotides at the transcription start site of the
MAGE-A11 gene promoter (2, 3). MAGE-A11 expression is
also up-regulated in prostate cancer during androgen depriva-
tion therapy by increasing levels of cAMP associated with
down-regulation of phosphodiesterases that degrade cAMP (2,
60 – 63). In this report, we extend the family of MAGE-A11
interacting partners to include the human ARF tumor suppres-
sor that targets MAGE-A11 for degradation by the proteasome
independent of lysine ubiquitination.
Our studies suggest that down-regulation of MAGE-A11 by
ARF represents a third mechanism that controls MAGE-A11,
where low levels of ARF contribute to higher levels of MAGE-
A11 during prostate cancer progression. Our findings are
consistent with the tumor suppressor activity of ARF that
protects normal cells from tumorigenesis and the proto-onco-
gene activity of MAGE-A11 that increases prostate cancer cell
growth. The increase in MAGE-A11 in prostate cancer during
androgen deprivation therapy provides an escape mechanism
whereby prostate cancer cells survive and expand in an envi-
ronment of low intratumoral active androgen biosynthesis.
Our studies suggest a model (Fig. 11) in which MAGE-A11 is
central to a protein network involved in human cell growth
regulation. We showed previously that MAGE-A11 increases
AR transcriptional activity by binding the AR NH2-terminal
FXXLF motif and recruiting p300 and TIF2 (NCOA2) tran-
scriptional coregulators, which increases androgen-dependent
prostate cancer cell growth (1, 10, 11, 38). Here we provide
evidence that MAGE-A11 interacts with and is targeted for
degradation by the proteasome by the human ARF tumor sup-
pressor. MAGE-A11 functions cooperatively with HDM2 E3
ubiquitin ligase to increase the transcriptional activity of E2F1,
an oncoprotein that promotes progression through the cell
cycle (5, 64). ARF inhibits the increase in AR and E2F1 tran-
scriptional activity induced by MAGE-A11. Multiple interac-
tion regions between ARF and HDM2 (65) were seen between
MAGE-A11 and ARF that resulted in MAGE-A11 degradation.
Inhibition of the stimulatory effects of MAGE-A11 on AR and
E2F1 transcriptional activity by ARF provides new mechanisms
of tumor suppression and maintenance of the nontransformed
phenotype (5, 42).
Low levels of ARF associated with cancer development result
from destabilization of the ARF protein or from INK4a/ARF
gene deletions, mutations, or methylation (66, 67). Low levels of
ARF in prostate cancer (19 –21) were also attributed to andro-
gen-inducible microRNA-125b that negatively regulates ARF
in prostate cancer (68). Our studies suggest that low levels of
ARF in prostate cancer increase the levels of MAGE-A11 by
decreasing MAGE-A11 degradation. Our findings are consis-
tent with the proto-oncogene properties associated with
increased levels of MAGE-A11 and with the tumor suppressor
activity of ARF. Increased expression of ARF was proposed
as a therapeutic approach to increase cancer sensitivity to
chemotherapy (69). Our findings suggest that prostate can-
cers with elevated levels of MAGE-A11 are candidates for
clinical intervention that increases ARF, which would decrease
MAGE-A11 and induce cell cycle arrest or apoptosis. The asso-
ciation between higher levels of MAGE-A11 and low ARF in
prostate cancer supports the concept that ARF maintains
low levels of MAGE-A11 in normal cells by promoting deg-
radation by the proteasome, and human ARF tumor suppres-
sor activity depends on the post-translational down-regulation
of MAGE-A11.
ARF Counteracts the Stimulatory Effects of MAGE-A11 on AR
Transcriptional Activity—Increased AR transcriptional activity
in response to low intratumoral androgen synthesis is a princi-
pal driver of castration-resistant prostate cancer (70, 71). AR
transcriptional activity also increases in response to higher lev-
els of MAGE-A11, which has been observed in 36% of castra-
tion-resistant prostate cancers (1, 2). Here we show that ARF
interferes with the stimulatory effects of MAGE-A11 on
androgen-dependent AR transcriptional activity and the con-
stitutive activity of a splice-variant-like AR reported in prostate
cancer (47– 49). The findings suggest that the inhibitory effects
FIGURE 9. ARF inhibits MAGE-A11 interaction with E2F1. A, ARF inhibition of E2F1 stabilization by MAGE-A11 was shown by expressing 2 g of pSG5 (lane
1) or 2 g of pSG5-MAGE without (lane 2) or with 2 g of pCI-neo-HA-ARF (lane 3) per 10-cm CV1 cell dish. pCMV-E2F1 (1 g) was expressed alone (lane 4) or with
2 g of pSG5-MAGE (lane 5), 2 g of pSG5-MAGE, and 2 g of pCI-neo-HA-ARF (lane 6) or 2 g of pCI-neo-HA-ARF (lane 7). pCI-neo-HA-ARF (2 g) was expressed
alone (lane 8). The immunoblot of cell extracts (80 g of protein/lane) was probed using E2F1, MAGE1, HA, and -actin antibodies. B, ARF inhibition of
MAGE-A11 interaction with E2F1 was shown by coimmunoprecipitation of MAGE-A11 and ARF with FLAG-E2F1 using 4 g of pCMV-FLAG (lanes 1–3) or
pCMV-FLAG-E2F1 (lanes 4 –7) alone (lane 4) or with 6 g of pCI-neo-HA-ARF (lanes 1 and 6), 4 g of pSG5-MAGE (lanes 2 and 5), or pCI-neo-HA-ARF and
pSG5-MAGE (lanes 3 and 7) per 10-cm COS1 cell dish. Immunoprecipitates (IP, top three panels) and cell extracts (60 g of protein/lane, bottom four panels) were
probed using MAGE2 antibody that does not cross-react with FLAG, FLAG-M2 for FLAG-E2F1, HA antibody for HA-ARF, and -actin antibodies. C, inhibition by
ARF of endogenous E2F1 transcriptional activity stimulated by MAGE-A11 was measured in HeLa cells using 0.1 g of E2F1-Luc in the presence of 0.1 g of
pSG5 empty vector () or 25, 50, or 100 ng of pSG5 () or pSG5-MAGE with or without 50 ng of pCI-neo-HA-ARF and/or 25 ng of pSG5-HA-p300. D,
dose-dependent ARF inhibition of MAGE-A11 stimulation of endogenous E2F1 transcriptional activity was determined in HeLa cells using 0.1 g of E2F1-Luc
and 0.1 g of pSG5 () or 0.1 g of pSG5-MAGE expressed with 50 ng of pCMV5 () or 10, 25, or 50 ng of pCI-neo-HA-ARF.
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of ARF on AR transcriptional activity are mediated in part by
down-regulation of MAGE-A11.
It was reported that ARF inhibits AR transcriptional activity
by interfering with the androgen-dependent AR NH2- and
COOH-terminal interaction (46) that stabilizes AR in the pres-
ence of AR agonists (14, 72) and that AR is degraded by the
proteasome in association with gene activation (73). We found
that ARF interferes with a positive relationship between AR and
MAGE-A11 by targeting MAGE-A11 for degradation. Al-
though ARF did not directly decrease AR levels, ARF negatively
regulated AR in the presence of MAGE-A11. Dependence on
MAGE-A11 interaction with the AR NH2-terminal FXXLF
motif for the effects of ARF provided evidence that ARF inter-
feres with AR transcriptional activity by negatively regulating
MAGE-A11. The inhibitory effects of ARF on AR transcrip-
tional activity evident without the increased expression of
MAGE-A11 suggest that negative regulation of AR by ARF
occurs even when MAGE-A11 levels are low (10).
Up-regulation of HDM2 by MAGE-A11 Increases E2F1 Tran-
scriptional Activity That Is Inhibited by ARF—HDM2 E3 ubiq-
uitin ligase is a proto-oncogene overexpressed in human
cancers and a target for anticancer therapy (74, 75). HDM2
stabilizes E2F1 and mediates ubiquitin-dependent degradation
of p53 (54). Here we show that MAGE-A11 cooperates with
HDM2 to stabilize and increase the transcriptional activity of
E2F1, an oncoprotein that up-regulates genes important for cell
FIGURE 10. Stabilization of HDM2 by MAGE-A11. A, stabilization of HDM2 by MAGE-A11 was shown on an immunoblot by expressing 6 g of pCMV5 (lane
1), 6 g of pCMV-HA2-HDM2 alone (lane 2), or with 3 g of pSG5-MAGE (lane 3) or 3 g of pSG5-MAGE alone (lane 4) per 10-cm COS1 cell dish. Cells were treated
with 5 ng/ml EGF for 24 h prior to harvest. The immunoblot of cell extracts (60 g of protein/lane) from an 8% acrylamide gel was probed using HA, MAGE1, and
-actin antibodies. The higher molecular weight form of HDM2 results from self-ubiquitination or sumoylation (56, 57). The 90-kDa HDM2 versus -actin band
intensity is shown in the lower panel. B, HDM2 stabilization by MAGE-A11 in the presence of ARF was shown on an immunoblot using 6 g of pCMV5 (lane 1),
6 g of pCMV-HA2-HDM2 alone (lane 2) or with 3 g of pSG5-MAGE (lane 3), or 3 g of pCI-neo-HA-ARF alone (lane 4) or with pSG5-MAGE and pCI-neo-HA-ARF
together (lane 5) per 10-cm dish of COS1 cells. pSG5-MAGE (3 g) was expressed alone (lane 6) or with 3 g of pCI-neo-HA-ARF (lane 7), or pCI-neo-HA-ARF was
expressed alone (lane 8). The immunoblot of cell extracts (50 g of protein/lane) from a 12% acrylamide gel was probed using HA, MAGE1, and -actin
antibodies. The 100-kDa HDM2 versus -actin band intensity is shown in the lower panel. C, E2F1 inhibition of HDM2 stabilization by MAGE-A11 was shown
on an immunoblot by expressing 3 g of pCMV5 (lane 1) or 3 g of pCMV-E2F1 alone (lane 2) or with 3 g of pSG5-MAGE (lane 3), 6 g of pCMV-HA2-HDM2 (lane
4), or with pSG5-MAGE and pCMV-HA2-HDM2 together (lane 5). pSG5-MAGE (3 g) was expressed alone (lane 6) or with 6 g of pCMV-HA2-HDM2 (lane 7) or
6 g of pCMV-HA2-HDM2 was expressed alone (lane 8) per 10-cm COS1 cell dish. The immunoblot of cell extracts (50 g of protein/lane) from a 12% acrylamide
gel was probed using HA, E2F1, MAGE1, and -actin antibodies. The 100-kDa HDM2 versus -actin band intensity is shown in the lower panel. D, additive
effects of MAGE-A11 and HDM2 on endogenous E2F1 transcriptional activity was determined in HeLa cells by expressing 0.1 g of E2F1-Luc with 25 ng of pSG5
with or without () 25 ng of CMV-HDM2 and 25 ng of MAGE-A11 alone or together. E, ARF inhibition of endogenous E2F1 transcriptional activity induced by
MAGE-A11, HDM2, and p300 was determined in HeLa cells by expressing 0.1 g of E2F1-Luc with 25 ng of pSG5 (), or 25 ng of pSG5-MAGE and 50 ng of
pSG5-HA-p300 with 50 ng of pCMV5 () or 50 ng of pCI-neo-HA-ARF, or 25 ng of pSG5-MAGE, 25 ng of pSG5-HA-p300, and 25 ng of pCMV-HDM2 with 50 ng
of pCMV5 () or 50 ng of pCI-neo-HA-ARF. F, p300 inhibition of HDM2 stabilization by MAGE-A11 was shown by expressing 6 g of pCMV5 (lane 1) or 6 g of
pCMV-HA2-HDM2 alone (lane 2) or with 3 g of pSG5-MAGE (lane 3), 6 g of pSG5-HA-p300 (lane 4) or pSG5-MAGE and pSG5-HA-p300 together (lane 5) per
10-cm COS1 cell dish. pSG5-MAGE was expressed alone (lane 6) or with pSG5-HA-p300 (lane 7), and pSG5-HA-p300 was expressed alone (lane 8). The immu-
noblot of cell extracts (60 g of protein/lane) from an 8% acrylamide gel was probed using p300, HA, MAGE1, and -actin antibodies.
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cycle progression (53–55). Our results suggest that MAGE-A11
is integral to a protein network involved in E2F1 regulation of
cell cycle progression. The ability of MAGE-A11 to increase
E2F1 transcriptional activity supports a critical role in prostate
cancer cell growth.
A principal function of the ARF tumor suppressor is inhibi-
tion of HDM2, which results in the stabilization of p53 and loss
of inhibition of E2F1. Both ARF and p53 tumor suppressor
activity protect normal cells from oncogene-induced tumor
formation (76). Previous studies suggested that ARF negatively
regulates E2F1 through increased E2F1 ubiquitination and pro-
teasome degradation (41, 53, 77). It was suggested that inhibi-
tion of E2F1-dependent transcriptional activity involves HDM2
and/or p53 (42, 78). We found that one function of ARF is
inhibition of MAGE-A11 interaction with E2F1, which inter-
feres with the stabilizing effects and transcriptional enhancing
effects of MAGE-A11. Negative feedback regulation is sug-
gested by the up-regulation of ARF and p53 by E2F1 that con-
tributes to the induction of apoptosis (79, 80). ARF also inter-
acts with c-myc and causes c-myc relocalization from the
nucleoplasm to nucleoli, inhibits c-myc transcriptional activa-
tion of genes required for cell cycle progression (81), and
induces sumoylation of its binding partners (57).
It remains to be determined what role MAGE-A11 has in the
regulation of p53 and whether stabilization of HDM2 by
MAGE-A11 interferes with ARF inhibition of HDM2 E3 ubiq-
uitin ligase activity that promotes p53 degradation and cell
cycle progression. It is not known how MAGE-A11 impacts
feedback regulation of p53, such as the increase in ARF expres-
sion when p53 is inhibited or increased expression of ARF and
p53 in response to cellular and viral oncogenes such as c-myc or
E1A (82). Stabilization and sequestration of MAGE-A11 and
HDM2 by ARF may be involved in feedback control (79). Fur-
thermore, HDM2 interaction with p300 is required for the pro-
teasomal degradation of p53 (75). MAGE-A11 forms a strong
complex with p300 in association with gene transcription (10)
that inhibited the stabilization of HDM2 by MAGE-A11. These
findings suggest that MAGE-A11 interaction with HDM2 and
p300 may be involved in HDM2 regulation of p53. Phosphory-
lation of HDM2 by Akt signals the nuclear localization of
HDM2. ARF inhibits nuclear export of HDM2 by the seques-
tration of HDM2 in nucleoli, where HDM2 no longer can
export p53 to the cytoplasm for degradation and thereby acti-
vates p53 (24, 50, 58, 83– 85). The impact of MAGE-A11 on
ARF and HDM2 regulation of p53 remains to be determined.
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